1.中国居民营养与慢性病状况报告(2020年)[J].营养学报,2020,42(6):521.
2. Zhou J, Zhou F, Wang W, et al. Epidemiological features of NAFLD from 1999 to 2018 in China[J]. Hepatology, 2020, 71(5): 1851-1864.
3.Mi B, Wu C, Gao X, Wu W, Du J, Zhao Y, Wang D, Dang S, Yan H. Long-term BMI change trajectories in Chinese adults and its association with the hazard of type 2 diabetes: evidence from a 20-year China Health and Nutrition Survey. BMJ Open Diabetes Res Care. 2020 Jul;8(1):e000879. doi: 10.1136/bmjdrc-2019-000879. PMID: 32719076; PMCID: PMC7389517.
4.陈兆斌,黄丽媛,王炳元,等.代谢相关脂肪性肝病与2 型糖尿病的关系及共病机制研究进展[J]. 临床肝胆病杂志, 2023,39(10): 2454-2459
5.范建高,徐小元,南月敏,等.代谢相关(非酒精性)脂肪性肝病防治指南(2024年版)[J].实用肝脏病杂志, 2024, 27(4):494-510.DOI:10.3760/cma.j.cn501113-20240327-00163.
6.Targher G, Bertolini L, Rodella S, Zoppini G, Lippi G, Day C, Muggeo M. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients. Diabetologia. 2008 Mar;51(3):444-50. doi: 10.1007/s00125-007-0897-4. Epub 2007 Dec 6. PMID: 18058083.
7.秦春梅,陆强,冯继,等.男性非酒精性脂肪性肝病患者血糖波动研究[J].中华内分泌代谢杂志, 2011, 27(9):3.DOI:10.3760/cma.j.issn.1000-6699.2011.09.008.
8.Hossain N, Afendy A, Stepanova M, Nader F, Srishord M, Rafiq N, Goodman Z, Younossi Z. Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009 Nov;7(11):1224-9, 1229.e1-2. doi: 10.1016/j.cgh.2009.06.007. Epub 2009 Jun 25. PMID: 19559819.
9.Younossi Z M,Gramlich T,Matteoni C A,et al.Nonalcoholic fatty liver disease in patients with type 2 diabetes[J].Clinical Gastroenterology and Hepatology, 2004,2(3):262-265.DOI:10.1016/S1542-3565(04)00014-X.
10.中华医学会内分泌学分会,中华医学会糖尿病学分会.中国成人2型糖尿病合并非酒精性脂肪性肝病管理专家共识 [J].中华内分泌代谢杂志,2021,37(7):589-598.
11.张宇.多烯磷脂酰胆碱联合二甲双胍治疗非酒精性脂肪肝疗效观察[J].实用临床医药杂志, 2013, 17(11):2.DOI:10.7619/jcmp.201311047.
12.尹笃钦,孔黎明.易善力治疗糖尿病性脂肪肝效果观察.齐鲁医学杂志,2000,15(4):277-278, DO1:10.3969/i.issn.1008-0341.2000.04.023